Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
Board on the Hill lobby day, Affordable Care Act Implementation, Medicaid, Medicare, budget and appropriations, National Institutes of Health and Food and Drug Administration funding, HR 2725 the FDA SOS Act
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2014 · first_quarter · RA
Board on the Hill lobby day, Affordable Care Act Implementation, Medicaid, Medicare, budget and appropriations, National Institutes of Health and Food and Drug Administration funding, HR 2725 the FDA SOS Act
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2013 · fourth_quarter · 4A
Source: Senate LDA
Board on the Hill lobby day, Affordable Care Act Implementation, Medicaid, Medicare, budget and appropriations, National Institutes of health and Food and Drug Administration funding, HR 2725 the FDA SOS Act
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
Board on the Hill lobby day, Affordable Care Act Implemention, Medicaid, Medicare, budget and appropriations, National Institutes of Health and Food and Drug Administration funding, HR 2725 the FDA SOS Act
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
Board on the Hill lobby day, Affordable Care Act Implementation, Medicaid, Medicare, budget and appropriations, National Institutes of health and Food and Drug Administration funding, HR 2725 the FDA SOS Act
House, Senate, FDA, Energy and Commerce and Labor-HHS Committee on Prescription Drug User Fee Act Agreement (PDUFA V), HR 4156, and S 2218; funding for National Center for Advancing Translational Sciences (NCATS) at NIH, FDA funding, NIH funding; FY13 Appropriations and Sequestration; CMS/Medicaid; Congressional CF Caucus; Patient Protection and Affordable Care Act and general health reform issues; Teen Advocacy Day and May Board on the Hill lobby days
House, Senate, FDA on EXPERRT Act (HR 4156, S 2218), Energy and Commerce and Labor-HHS Committee on Prescription Drug User Fee Act Agreement (PDUFA V), funding for National Center for Advancing Translational Sciences (NCATS) at NIH, FDA funding, NIH funding, Appropriations testimony, FTC on MedCo ExpressScripts merger, CMS on Medicare and Medicaid, Congressional CF Caucus, HHS comments on health reform and other regulations, FDA on Kalydeco
To amend title 38, United States Code, to provide for penalties for employees of the Veterans Health Administration who intentionally fail to follow infection control practices.
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
To amend title 38, United States Code, to provide for penalties for employees of the Veterans Health Administration who intentionally fail to follow infection control practices.
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
To amend title 38, United States Code, to provide for penalties for employees of the Veterans Health Administration who intentionally fail to follow infection control practices.
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
To amend title 38, United States Code, to provide for penalties for employees of the Veterans Health Administration who intentionally fail to follow infection control practices.
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
To amend title 38, United States Code, to provide for penalties for employees of the Veterans Health Administration who intentionally fail to follow infection control practices.
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
To amend title 38, United States Code, to provide for penalties for employees of the Veterans Health Administration who intentionally fail to follow infection control practices.
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
To amend title 38, United States Code, to provide for penalties for employees of the Veterans Health Administration who intentionally fail to follow infection control practices.
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
To amend title 38, United States Code, to provide for penalties for employees of the Veterans Health Administration who intentionally fail to follow infection control practices.
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
To amend title 38, United States Code, to provide for penalties for employees of the Veterans Health Administration who intentionally fail to follow infection control practices.
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
Appropriations for FDA and NIH; HR 2866 the Improving Access to Clinical Trials Act of 2009; GAO Nominations to the Patient-Centered Outcomes Research Institute; SSA compassionate allowance; CMS - Home Infusion; HR 4926 Medical Foods Act;
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
Appropriations for FDA and NIH; HR 2866 the Improving Access to Clinical Trials Act of 2009; GAO Nominations to the Patient-Centered Outcomes Research Institute; SSA compassionate allowance; CMS - Home Infusion; HR 4926 Medical Foods Act;
Improving Access to Clinical Trials Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Don't Ask, Don't Tell Repeal Act of 2010
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Don't Ask, Don't Tell Repeal Act of 2010
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Don't Ask, Don't Tell Repeal Act of 2010
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Don't Ask, Don't Tell Repeal Act of 2010
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Don't Ask, Don't Tell Repeal Act of 2010
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Don't Ask, Don't Tell Repeal Act of 2010
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Don't Ask, Don't Tell Repeal Act of 2010
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Don't Ask, Don't Tell Repeal Act of 2010
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Don't Ask, Don't Tell Repeal Act of 2010
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
Medical Foods Equity Act of 2010
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
Appropriations for FDA and NIH; HR 2866 the Improving Access to Clinical Trials Act of 2009; GAO Nominations to the Patient-Centered Outcomes Research Institute; SSA compassionate allowance; CMS - Home Infusion; HR 4926 Medical Foods Act;
Medical Foods Equity Act of 2010
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
Appropriations for FDA and NIH; HR 2866 the Improving Access to Clinical Trials Act of 2009; GAO Nominations to the Patient-Centered Outcomes Research Institute; SSA compassionate allowance; CMS - Home Infusion; HR 4926 Medical Foods Act;
Energy Development Program Implementation Act of 2009
Client: CYSTIC FIBROSIS FOUNDATION · Firm: CYSTIC FIBROSIS FOUNDATION
Clinical research S. 1675 "Improving Access to Clinical Trials Act" passage & implementation; Health care reform & implementation including B. Marshalls PCORI nomination, comment submissions; FDA funding & processes; NIH funding & processes; CMS coverage decisions including: home IV & DME; 340B Drug Pricing Program; FDA drug approval process
Board on the Hill lobby day, Affordable Care Act Implementation, Medicaid, Medicare, budget and appropriations, National Institutes of health and Food and Drug Administration funding, HR 2725 the FDA SOS Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA)
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2013 · fourth_quarter · Q4
Board on the Hill lobby day, Affordable Care Act Implementation, Medicaid, Medicare, budget and appropriations, National Institutes of health and Food and Drug Administration funding, HR 2725 the FDA SOS Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA)
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2013 · fourth_quarter · Q4
Board on the Hill lobby day, Affordable Care Act Implemention, Medicaid, Medicare, budget and appropriations, National Institutes of Health and Food and Drug Administration funding, HR 2725 the FDA SOS Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA)
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2013 · third_quarter · Q3
Funding for the National Institutes of Health and Food and Drug Administration, Social Security Disability Insurance proposed eligibility changes, Congressional Cystic Fibrosis Caucus, Hawaii Care Center advocacy, access to cystic fibrosis care under the Patient Protection and Affordable Care Act
Filing targets: Army, Dept of (Other), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA)
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2013 · second_quarter · Q2
Teen Advocacy Day, Board on the Hill, funding for the National Institutes of Health and Food and Drug Administration, Social Security Disability Insurance proposed eligibility changes, Congressional Cystic Fibrosis Caucus, Hawaii Care Center advocacy, health reform access to care measures
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA)
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2013 · first_quarter · Q1
Board on the Hill and March on the Hill advocacy days, Sequestration, NIH-FDA Budget, FDA Breakthrough Designation, Prescription Drug User Fee Act Congressional follow up, International CF project, Lasker award congressional support, federal budget and appropriations, Social Security Disability Insurance eligibility changes, Medicaid cost-sharing
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA)
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2012 · fourth_quarter · Q4
American Thoracic Society briefing, FDA, NIH, Sequestration, Fiscal Cliff and Budget, Hawaii Care Center access for civilians, Rare Disease Legislative Advocates briefing, international patient visa issue, Board on the Hill event, ACA comments (Essential Health Benefits, Medicaid Expansion, Insurance Exchanges), CMS Comments
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2012 · third_quarter · Q3
FDA (EXPERRT, PDUFA) follow up, Board on the Hill, Appropriations and Sequestration (NIH & FDA), Teen Advocacy Day follow up, Congressional CF Caucus, Congressional Briefings, Make Every Breath Count grassroots campaign, 340B, Meeting with White House Science and Technology office, communications to grassroots advocates, Essential Health Benefits & Exchanges under PPACA, coverage for Kalydeco, Medicaid drug coverage
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2012 · second_quarter · Q2
House, Senate, FDA, Energy and Commerce and Labor-HHS Committee on Prescription Drug User Fee Act Agreement (PDUFA V), HR 4156, and S 2218; funding for National Center for Advancing Translational Sciences (NCATS) at NIH, FDA funding, NIH funding; FY13 Appropriations and Sequestration; CMS/Medicaid; Congressional CF Caucus; Patient Protection and Affordable Care Act and general health reform issues; Teen Advocacy Day and May Board on the Hill lobby days
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2012 · first_quarter · Q1
House, Senate, FDA on EXPERRT Act (HR 4156, S 2218), Energy and Commerce and Labor-HHS Committee on Prescription Drug User Fee Act Agreement (PDUFA V), funding for National Center for Advancing Translational Sciences (NCATS) at NIH, FDA funding, NIH funding, Appropriations testimony, FTC on MedCo ExpressScripts merger, CMS on Medicare and Medicaid, Congressional CF Caucus, HHS comments on health reform and other regulations, FDA on Kalydeco
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA)
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2011 · fourth_quarter · Q4
Medicaid, Medicare, Deficit Reduction Committee-re: protecting Medicaid from budget cuts, PDUFA, FTC on Medco Express Scripts merger, review of FDA reform and messaging, NIH and FDA funding, NCATS establishment at NIH, TREAT Act, Health Care Reform implementation, strategic planning for grassroots agenda
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA)
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2011 · third_quarter · Q3
NIH, FDA, L-HHS Appropriations; NCATS establishment and funding; CMS, SSA and Congress on Medicare and Medicaid funding and coverage decisions; CF Caucus support; Energy and Commerce Committee on PDUFA and general strategies; HHS comments and statements on health reform and other regulations
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA)
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2011 · third_quarter · RA
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2011 · second_quarter · 2A
NIH, FDA, L-HHS Appropriations, FDA Appropriations, PDUFA & general strategies, CMS coverage decisions OIG (Pari nebulizer) & HCPCS coding for Hypertonic Saline, Medicaid and Medicare, SSA- Improving Access to Clinical Trials Act, SBIR, Health care reform implementation ACO comments, CF Caucus
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA)
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2011 · second_quarter · Q2
NIH, FDA, L-HHS Appropriations, FDA Appropriations, PDUFA & general strategies, CMS coverage decisions OIG (Pari nebulizer) & HCPCS coding for Hypertonic Saline, Medicaid and Medicare, SSA- Improving Access to Clinical Trials Act, SBIR, Health care reform implementation ACO comments, CF Caucus
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA)
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2011 · first_quarter · Q1
FDA & NIH appropriations, NIH - NCATS, CMS - coverage for CF drugs & health reform implementation, SSA Improving Access to Clinical Trials Act implementation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA)
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2010 · fourth_quarter · 4A
Healthcare reform; NIH & FDA appropriations; FDA reauthorization; CMS - device & home IV coverage; FDA- Prescription Drug User Fee Act, 340B Drug Pricing Program; Social Security Administration re: "Improving Access to Clinical Trials Act" implementation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Social Security Administration (SSA)
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2010 · second_quarter · 2A
Appropriations for FDA and NIH; HR 2866 the Improving Access to Clinical Trials Act of 2009; GAO Nominations to the Patient-Centered Outcomes Research Institute; SSA compassionate allowance; CMS - Home Infusion; HR 4926 Medical Foods Act;
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA)
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2010 · fourth_quarter · Q4
Healthcare reform; NIH & FDA appropriations; FDA reauthorization; CMS - device & home IV coverage; FDA- Prescription Drug User Fee Act, 340B Drug Pricing Program; Social Security Administration re: "Improving Access to Clinical Trials Act" implementation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Social Security Administration (SSA)
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2010 · third_quarter · Q3
Clinical research S. 1675 "Improving Access to Clinical Trials Act" passage & implementation; Health care reform & implementation including B. Marshalls PCORI nomination, comment submissions; FDA funding & processes; NIH funding & processes; CMS coverage decisions including: home IV & DME; 340B Drug Pricing Program; FDA drug approval process
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Social Security Administration (SSA)
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2010 · second_quarter · Q2
Appropriations for FDA and NIH; HR 2866 the Improving Access to Clinical Trials Act of 2009; GAO Nominations to the Patient-Centered Outcomes Research Institute; SSA compassionate allowance; CMS - Home Infusion; HR 4926 Medical Foods Act;
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA)
CYSTIC FIBROSIS FOUNDATION via CYSTIC FIBROSIS FOUNDATION
2010 · second_quarter · RA
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care
research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care